TY - JOUR AU - Liang, Wenhua AU - Cai, Kaican AU - Chen, Chun AU - Chen, Haiquan AU - Fang, Wentao AU - Fu, Junke AU - Fu, Xiangning AU - Gao, Shugeng AU - Hu, Jian AU - Huang, Yunchao AU - Jiang, Ganning AU - Jiao, Wenjie AU - Li, Shanqing AU - Li, Gaofeng AU - Li, Hecheng AU - Li, Hui AU - Li, Xiaofei AU - Liang, Naixin AU - Liu, Deruo AU - Liu, Hongxu AU - Liu, Jun AU - Liu, Lunxu AU - Liu, Yang AU - Luo, Qingquan AU - Ma, Haitao AU - Mao, Weimin AU - Peng, Zhongmin AU - Qiao, Guibin AU - Shao, Guoguang AU - Tan, Lijie AU - Tan, Qunyou AU - Wang, Qun AU - Wang, Changli AU - Wu, Qingchen AU - Xu, Shidong AU - Xu, Songtao AU - Xu, Lin AU - Yang, Yue AU - Yu, Fenglei AU - Zhang, Baijiang AU - Zhang, Lanjun AU - Zhao, Bo AU - Zhi, Xiuyi AU - Brunelli, Alessandro AU - Petersen, René Horsleben AU - Liu, Chia-Chuan AU - Ricciuti, Biagio AU - Metro, Giulio AU - Tuzi, Alessandro AU - Suter, Matteo B. AU - Evison, Matthew AU - Seki, Nobuhiko AU - Sasada, Shinji AU - Izumo, Takhiro AU - Cho, William Chi-Shing AU - He, Jianxing AU - National Clinical Research Center for Respiratory Disease, written on behalf of AU - China International Exchange and Promotion Association for Medical and Healthcare, Thoracic Surgery Branch of AU - AME Thoracic Surgery Collaborative Group, Chinese Alliance Against Lung Cancer and PY - 2019 TI - Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition) JF - Translational Lung Cancer Research; Vol 8, No 6 (December 31, 2019): Translational Lung Cancer Research Y2 - 2019 KW - N2 - Non-small cell lung cancer (NSCLC) is the most common and fatal tumor worldwide, with 2.1 million new cases and 1.77 million deaths per year (1). With the wider application of examination approaches and the improvement of health awareness, higher proportions of surgically resectable early and mid-stage lung cancers have been detected. In overall, only 50% of patients have been cured after radical resection. In other cases, however, NSCLC is highly active and recurrence and/or metastasis can easily occur after surgery. In these patients, systemic therapy as a postoperative adjuvant therapy is required to eliminate or reduce residual micro-lesions to lower the risk of recurrence; meanwhile, the patients should be closely monitored to detect early recurrence. EGFR mutation is a major mutation type in lung cancer, and is seen in about 40% of lung cancer cases in Asia (2). Compared with wild types and other mutation types, EGFR-mutant NSCLC has its unique biological properties and drug susceptibilities, and thus requires specific diagnosis and treatment strategies. This expert consensus aims to review the current evidence and provide recommendations on key issues. UR - https://tlcr.amegroups.org/article/view/34453